NRX Pharmaceuticals (NRXP) Assets Average (2018 - 2026)

NRX Pharmaceuticals (NRXP) has 9 years of Assets Average data on file, last reported at $12.4 million in Q1 2026.

• On a quarterly basis, Assets Average rose 121.15% year-over-year to $12.4 million in Q1 2026; TTM through Mar 2026 was $12.4 million, a 121.15% increase from a year earlier, with the FY2025 full-year figure at $8.3 million, up 51.44% from the prior year.
• Assets Average for Q1 2026 stood at $12.4 million, down from $14.0 million in the prior quarter.
• Over the last five years, Assets Average for NRXP reached as high as $38.2 million in Q1 2022 and fell as low as $4.1 million in Q4 2024.
• Historically, Assets Average has averaged $15.8 million across 5 years, with a median of $12.4 million in 2026.
• Across the five-year window, Assets Average jumped 751.05% in 2022 and slumped 78.23% in 2024, its largest moves.
• Year by year, Assets Average stood at $25.3 million in 2022, then sank by 59.67% to $10.2 million in 2023, then plunged by 60.28% to $4.1 million in 2024, then soared by 244.53% to $14.0 million in 2025, then declined by 11.07% to $12.4 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $12.4 million in Q1 2026, $14.0 million in Q4 2025, and $9.9 million in Q3 2025.